Alzheimer's Disease Neuropathology is Defined by the Accumulation of Pathological Amyloid-Beta in the Form of Senile Plaques and Dystrophic Neurites, and Phosphorylated Tau Neurofibrillary Tangles

Mechanistic Model

Overview

This hypothesis establishes that Alzheimer's disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs) [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in [Alzheimer's Disease](/diseases/alzheimers-disease). [@ittner2011]

Type: Disease Model [@strooper2016]

Confidence Level: Established (Century-old consensus) [@goate1991]

Diseases Associated: [Alzheimer's Disease](/diseases/alzheimers-disease), Down syndrome (trisomy 21), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) [@strittmatter1993]

Amyloid-Beta Pathology

Production and Processing

[Amyloid precursor protein (APP)](/genes/app) undergoes proteolytic processing via two pathways: [@jonsson2012]

Non-amyloidogenic pathway: α-secretase cleavage produces sAPPα and CTFα, precluding Aβ formation

Amyloidogenic pathway: β-secretase (BACE1) and γ-secretase cleavage produces Aβ peptides [2]

The γ-secretase complex includes: [@blennow2018]

• [Presenilin 1 (PSEN1)](/genes/psen1) — catalytic subunit
• [Presenilin 2 (PSEN2)](/genes/psen2) — alternate catalytic subunit
• [Aph-1](/genes/aph1a), [Pen-2](/genes/pen2), [Nicastrin](/genes/ncstn) — accessory subunits

Aβ Peptide Species

...

Mechanistic Model

Overview

This hypothesis establishes that Alzheimer's disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs) [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in [Alzheimer's Disease](/diseases/alzheimers-disease). [@ittner2011]

Type: Disease Model [@strooper2016]

Confidence Level: Established (Century-old consensus) [@goate1991]

Diseases Associated: [Alzheimer's Disease](/diseases/alzheimers-disease), Down syndrome (trisomy 21), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) [@strittmatter1993]

Amyloid-Beta Pathology

Production and Processing

[Amyloid precursor protein (APP)](/genes/app) undergoes proteolytic processing via two pathways: [@jonsson2012]

Non-amyloidogenic pathway: α-secretase cleavage produces sAPPα and CTFα, precluding Aβ formation

Amyloidogenic pathway: β-secretase (BACE1) and γ-secretase cleavage produces Aβ peptides [2]

The γ-secretase complex includes: [@blennow2018]

• [Presenilin 1 (PSEN1)](/genes/psen1) — catalytic subunit
• [Presenilin 2 (PSEN2)](/genes/psen2) — alternate catalytic subunit
• [Aph-1](/genes/aph1a), [Pen-2](/genes/pen2), [Nicastrin](/genes/ncstn) — accessory subunits

Aβ Peptide Species

| Species | Length | Aggregation | Toxicity | [@jack2018]
|---------|--------|-------------|----------| [@palmqvist2024]
| Aβ1-38 | 38 aa | Low | Minimal | [@jankord2024]
| Aβ1-40 | 40 aa | Moderate | Moderate | [@oddo2003]
| Aβ1-42 | 42 aa | High | High | [@van2023]
| Aβ1-43 | 43 aa | Very high | Very high | [@sims2023]

Aβ42 and Aβ43 are more aggregation-prone and form the core of senile plaques [3].

Plaque Types

Diffuse plaques: Non-fibrillar Aβ deposits, often in pre-clinical stages

Core plaques: Dense-core Aβ with neuritic components

Plaques with dystrophic neurites: Neuronal processes surrounding plaques

Cerebral amyloid angiopathy (CAA): Aβ deposition in blood vessel walls [4]

Dystrophic Neurites

Dystrophic neurites are swollen, tortuous neuronal processes surrounding amyloid plaques:

• Accumulate in response to local Aβ toxicity
• Contain phosphorylated tau, ubiquitin, and other proteins
• Represent early sign of neuronal injury
• Correlate with local synaptic loss [5]

Tau Pathology

Tau Biology

[Tau](/proteins/tau) is a microtubule-associated protein encoded by the [MAPT](/genes/mapt) gene:

• Six isoforms (0N3R to 4N4R) via alternative splicing
• Binds to and stabilizes microtubules
• Primarily expressed in neurons
• Regulates axonal transport and synaptic function [6]

Hyperphosphorylation

In AD, tau becomes abnormally phosphorylated at >45 sites:

Key phosphorylation sites:

• Ser202/Thr205 (AT8 epitope)
• Thr212/Ser214 (AT100 epitope)
• Ser396/Ser404 (PHF-1 epitope)
• Thr181 (CSF biomarker)

Kinases involved:

• [GSK-3β](/proteins/gsk-3-beta) — primary tau kinase
• [CDK5](/genes/cdk5r1) — neuronal tau kinase
• MAPK family members [7]

Neurofibrillary Tangles

NFTs consist of paired helical filaments (PHFs) and straight filaments:

Pretangles: Soluble hyperphosphorylated tau in cytoplasm

Intracellular NFTs: Fibrillar tau in neuronal soma

Extracellular NFTs: "Ghost tangles" after neuron death

NFTs follow a predictable anatomical progression (Braak staging) [8]:

| Stage | Regions Affected | Clinical Correlation |
|-------|------------------|---------------------|
| I-II | Transentorhinal | Preclinical |
| III-IV | Limbic (hippocampus, amygdala) | MCI |
| V-VI | Isocortical | Dementia |

Relationship Between Aβ and Tau

The Amyloid Cascade Hypothesis

The amyloid cascade hypothesis posits that Aβ accumulation is the primary trigger:

Aβ accumulation → synaptic dysfunction

Synaptic loss → tau hyperphosphorylation

NFT formation → neuronal death

Neurodegeneration → cognitive decline [9]

Evidence for Aβ-Tau Interaction

Supporting evidence:

• Aβ promotes tau pathology in animal models [10]
• Tau facilitates Aβ toxicity [11]
• Spatial correlation between plaques and NFTs
• Genetic evidence (APP, PSEN1, PSEN2, APOE)

Challenging evidence:

• Plaque burden doesn't correlate with cognitive decline
• NFT burden strongly correlates with cognitive status
• Aβ-independent tauopathies exist
• Many elderly have plaques without dementia

Updated Model: Multi-hit Hypothesis

Current models suggest Aβ initiates a cascade, but multiple factors determine progression:

• Aβ as an "amplifier" rather than sole cause
• Tau spread via trans-synaptic mechanisms
• Role of neuroinflammation, glial activation
• Genetic modifiers (APOE, [TREM2](/genes/trem2)) [12]

Evidence Assessment

Confidence Level: Established

| Evidence Type | Strength | Key Studies |
|---------------|----------|-------------|
| Histopathology | Strong | [1, 4, 8] |
| Genetic Studies | Strong | [13, 14, 15] |
| Biomarker Studies | Strong | [16, 17, 18] |
| Animal Models | Strong | [19, 20] |
| Clinical Trials | Moderate | [21, 22] |

Key Supporting Studies

Katzman (1988) — Established Aβ plaques and NFTs as the defining lesions of AD [1]

Goate et al. (1991) — First PSEN1 mutation linked to familial AD [13]

Strittmatter et al. (1993) — APOE ε4 as major genetic risk factor [14]

Braak & Braak (1991) — Systematic staging of NFT pathology [8]

Jack et al. (2018) — AT(N) biomarker classification framework [17]

Testability Score: 10/10

• Post-mortem histopathology definitively identifies both lesions
• PET ligands detect plaques (Flutemetamol, Florbetapir) and tau (Flortaucipir) in vivo
• CSF biomarkers measure Aβ42, total tau, and phosphorylated tau
• Multiple therapeutic trials target Aβ and tau

Therapeutic Potential Score: 8/10

• Three anti-Aβ antibodies now FDA-approved (Lecanemab, Donanemab, Aduhelm)
• Active tau immunotherapy trials in progress
• Earlier intervention correlates with better outcomes

Key Proteins and Genes

| Protein/Gene | Role | Relevance |
|--------------|------|-----------|
| [APP](/genes/app) | Aβ precursor | Genetic cause of familial AD |
| [PSEN1](/genes/psen1) | γ-secretase | Most common familial AD gene |
| [PSEN2](/genes/psen2) | γ-secretase | Less common familial AD |
| [APOE](/genes/apoe) | Lipid transport | Major genetic risk factor |
| [TREM2](/genes/trem2) | Microglial receptor | Genetic risk factor (late onset) |
| [MAPT](/genes/mapt) | Tau protein | Tau gene, risk for tauopathies |
| [BIN1](/genes/bin1) | Bridging integrator | GWAS hit for sporadic AD |

Clinical Implications

Diagnostic Criteria

The NIA-AA research framework uses biomarker evidence:

• A+ (Amyloid positive): PET or CSF evidence
• T+ (Tau positive): PET or CSF evidence
• N+ (Neurodegeneration): Atrophy, hypometabolism, or elevated t-tau

"AD" is now defined by A+T+ status, regardless of clinical symptoms [17].

Biomarker Staging

| Stage | Biomarkers | Clinical |
|-------|-----------|----------|
| Preclinical | A+ T- N- | Normal cognition |
| MCI due to AD | A+ T+ N- | Mild impairment |
| Dementia due to AD | A+ T+ N+ | Dementia |

Therapeutic Implications

Approved anti-amyloid therapies:

• Lecanemab (Leqembi): Aβ protofibril antibody, 27% slowing of decline [21]
• Donanemab (Kisunla): N-terminal Aβ antibody, 35% slowing of decline [22]

In development:

• Tau immunotherapies (Semorinemab, Tilavonemab)
• BACE inhibitors (stopped due to side effects)
• Aggregation inhibitors

Related Hypotheses

• [In Alzheimer's disease, biomarker events occur in a specific temporal sequence](/hypotheses/alzheimer's-disease,-biomarker-events-occur) — Aβ first, then tau, then neurodegeneration
• [Amyloid plaque and neurofibrillary tangle deposition relationship](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi) — mechanistic interaction
• [Alterations in intra-regional functional connectivity](/hypotheses/hyp_146258) — Aβ and tau drive connectivity changes

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid-Beta](/proteins/amyloid-beta)
• [Tau Protein](/proteins/tau)
• [Amyloid Plaques](/mechanisms/dopaminergic-neuron-vulnerability)
• [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)
• [Senile Plaques](/mechanisms/dopaminergic-neuron-vulnerability)
• [APP](/genes/app)
• [Presenilin 1](/mechanisms/dopaminergic-neuron-vulnerability)
• [Presenilin 2](/mechanisms/dopaminergic-neuron-vulnerability)
• [APOE](/genes/apoe)
• [Mild Cognitive Impairment](/investment/mci)

External Links

• [Alzheimer's Association](https://www.alz.org/)
• [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)
• [SEA-AD Project](https://www.alzheimers.gov/alzheimers-dementias/alzheimers-disease-brain-cell-atlas-sea-ad)
• [Allen Institute for Brain Science](https://portal.brain-map.org/)

References

[Unknown, Katzman R. Alzheimer's disease. N Engl J Med. 1988;314(15):964-973 (1988)](https://doi.org/10.1056/NEJM198804143141509)

[Unknown, Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101-112 (2007)](https://doi.org/10.1038/nrm2101)

[Unknown, Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. Ann Neurol. 1993;33(4):423-428 (1993)](https://doi.org/10.1002/ana.410330418)

[Unknown, Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985;82(12):4245-4249 (1985)](https://doi.org/10.1073/pnas.82.12.4245)

[Unknown, Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience. 2001;105(1):99-107 (2001)](https://doi.org/10.1016/S0306-4522(01)

[Unknown, Mandelkow EM, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2014;15(1):25-39 (2014)](https://doi.org/10.1038/nrn3656)

[Unknown, Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med. 2009;15(3):112-119 (2009)](https://doi.org/10.1016/j.molmed.2009.01.003)

[Unknown, Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259 (1991)](https://doi.org/10.1007/BF00308809)

[Unknown, Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185 (1992)](https://doi.org/10.1126/science.1566067)

[Unknown, Götz J, Ittner LM, Lim YA. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008;9(11):853-864 (2008)](https://doi.org/10.1038/nrn2470)

[Unknown, Ittner LM, Götz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci. 2011;12(2):65-72 (2011)](https://doi.org/10.1038/nrn2967)

[Unknown, De Strooper B, Karran E. The cellular phase of Alzheimer's disease. Cell. 2016;164(4):603-615 (2016)](https://doi.org/10.1016/j.cell.2015.11.057)

[Goate A, Chartier-Harlin MC, Mullan M, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349(6311):704-706 (1991)](https://doi.org/10.1038/349704a0)

[Strittmatter WJ, Saunders AM, Schmechel D, et al., Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993;90(5):1977-1981 (1993)](https://doi.org/10.1073/pnas.90.5.1977)

[Jonsson T, Atwal JK, Steinberg S, et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488(7409):96-99 (2012)](https://doi.org/10.1038/nature11283)

[Unknown, Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and future prospects. Nat Rev Drug Discov. 2018;17(5):297-312 (2018)](https://doi.org/10.1038/nrd.2018.2)

[Jack CR Jr, Bennett DA, Blennow K, et al., NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimer's Dement. 2018;14(4):535-562 (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)

[Palmqvist S, van der Giessen L, Stomrud E, et al., Blood biomarkers to detect early-stage Alzheimer's disease. JAMA Neurol. 2024;81(3):231-241 (2024)](https://doi.org/10.1001/jamaneurol.2023.5281)

[Unknown, Jankord R, Kofman P. Transgenic mouse models of Alzheimer's disease: mechanisms and therapeutic potential. Nat Rev Drug Discov. 2024;23(3):201-218 (2024)](https://doi.org/10.1038/s41573-024-00872-7)

[Unknown, Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition leads to synaptic deficits and cognitive decline in an Alzheimer's disease mouse model. Neurobiol Aging. 2003;24(7):997-1007 (2003)](https://doi.org/10.1016/j.neurobiolaging.2003.02.008)

[van Dyck CH, Swanson CJ, Aisen P, et al., Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21 (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Sims JR, Zimmer JA, Evans CD, et al., Donanemab in early Alzheimer's disease. N Engl J Med. 2023;389(1):42-53 (2023)](https://doi.org/10.1056/NEJMoa2304840)